Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertension

References

• Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119.
   PubMed Web of Science ®Google Scholar
• Tuder RM, Marecki JC, Richter A, et al. Pathology of pulmonary hypertension. Clin Chest Med. 2007; 28(1):23–42, vii.
   PubMed Web of Science ®Google Scholar
• Guignabert C, Tu L, Le Hiress M, et al. Pathogenesis of pulmonary arterial hypertension: lessons from cancer. Eur Respir Rev. 2013;22(130):543–551.
   PubMedGoogle Scholar
• Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulm Circ. 2021;11(1):2045894020977300.
   Web of Science ®Google Scholar
• Frost AE, Badesch DB, Barst RJ, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US contemporary registries. Chest. 2011;139(1):128–137.
   PubMed Web of Science ®Google Scholar
• American Lung Association. Learn about pulmonary arterial hypertension. [cited 2022 Apr 20]. Available from: https://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-arterial-hypertension/learn-about-pulmonary-arterial-hypertension
   Google Scholar
• Farber HW, Miller DP, Poms AD, et al. Five-year outcomes of patients enrolled in the REVEAL registry. Chest. 2015;148(4):1043–1054.
   PubMed Web of Science ®Google Scholar
• Montani D, Chaumais MC, Guignabert C, et al. Targeted therapies in pulmonary arterial hypertension. Pharmacol Ther. 2014;141(2):172–191.
   PubMed Web of Science ®Google Scholar
• Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest. 2012;142(2):448–456.
   PubMed Web of Science ®Google Scholar
• Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–3731.
   PubMed Web of Science ®Google Scholar
• Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889.
   PubMed Web of Science ®Google Scholar
• Zheng YG, Ma H, Hu EC, et al. Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials. Pulm Pharmacol Ther. 2014; 29(2):241–249.
   PubMed Web of Science ®Google Scholar
• Song C, Kunovszki P, Beaudet A. Comparison of healthcare encounters and drug persistence in patients with pulmonary arterial hypertension receiving oral selexipag, inhaled iloprost, or parenteral treprostinil: a retrospective database analysis. J Health Econ Outcomes Res. 2022;9(1):151–160.
   PubMedGoogle Scholar
• Momoi M, Hiraide T, Shinya Y, et al. Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension. Respir Med Case Rep. 2022;36:101592.
   PubMed Web of Science ®Google Scholar
• Kallen AJ, Lederman E, Balaji A, et al. Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol. 2008;29(4):342–349.
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425–1436.
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296–301.
   PubMed Web of Science ®Google Scholar
• Farber HW, Gin-Sing W. Practical considerations for therapies targeting the prostacyclin pathway. Eur Respir Rev. 2016;25(142):418–430.
   PubMed Web of Science ®Google Scholar
• Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med. 2021;384(4):325–334.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Waxman A, Rajagopal S, et al. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. Lancet Respir Med. 2021;9(11):1266–1274.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Drug approval package: orenitram (treprostinil) extended release tablets [Internet]; [cited 2022 May 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203496Orig1s000TOC.cfm
   Google Scholar
• White RJ, Jerjes-Sanchez C, Bohns Meyer GM, et al. Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial. Am J Respir Crit Care Med. 2020;201(6):707–717.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915–1922.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Actelion receives US FDA approval of uptravi (selexipag) for the treatment of pulmonary arterial hypertension | Fierce Pharma [Internet]; [cited 2022 Apr 20]. Available from: https://www.fiercepharma.com/pharma/actelion-receives-us-fda-approval-of-uptravi-selexipag-for-treatment-of-pulmonary-arterial
   Google Scholar
• Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–2533.
   PubMed Web of Science ®Google Scholar
• Phatak H, Pena JDO, Patel K, et al. PRO18 a systematic literature review of the economic burden and cost drivers in pulmonary arterial hypertension. Value in Health. 2021;24:S200–S201.
   Google Scholar
• McCaffrey DF, Burgette LF, Griffin BA, et al. Propensity scores for multiple treatments: a tutorial for the MNPS macro in the TWANG SAS macros [Internet]. RAND Corporation; 2015 Mar [cited 2022 May 5]. Available from: https://www.rand.org/pubs/tools/TL169z1.html
   Google Scholar
• McCaffrey DF, Griffin BA, Almirall D, et al. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med. 2013;32(19):3388–3414.
   PubMed Web of Science ®Google Scholar
• Nass SJ, Levit LA, Gostin LO, Rule I of M (US) C on HR and the P of HITHP. HIPAA, the privacy rule, and its application to health research [Internet]. Beyond the HIPAA privacy rule: enhancing privacy, improving health through research. National Academies Press (US); 2009 [cited 2022 Jun 27]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK9573/
   Google Scholar
• Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009; 54(1 Suppl):S43–S54.
   PubMed Web of Science ®Google Scholar
• Canavan N. Rehospitalization is driving costs in pulmonary arterial hypertension. Am Health Drug Benefits. 2013;6(9):600–601.
   PubMedGoogle Scholar
• McConnell JW, Tsang Y, Pruett J, et al. Comparative effectiveness of oral prostacyclin pathway drugs on hospitalization in patients with pulmonary hypertension in the United States: a retrospective database analysis. Pulm Circ. 2020;10(4):2045894020911831.
   Web of Science ®Google Scholar
• Dean BB, Saundankar V, Stafkey-Mailey D, et al. Medication adherence and healthcare costs among patients with pulmonary arterial hypertension treated with oral prostacyclins: a retrospective cohort study. Drugs Real World Outcomes. 2020;7(3):229–239.
   PubMedGoogle Scholar
• Solakidi A, Tzanetakos C, Beaudet A, et al. Cost-Effectiveness of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Greece. Value in Health. 2017;20(9):A645.
   Web of Science ®Google Scholar